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Objective. We hypothesize that treatment with Pravastatin, a HMG CoA reductase inhibitor would improve flow-mediated
dilation (FMD), a nitric oxide dependent phenomenon and the earliest detectable marker of endothelial dysfunction, in
asymptomatic patients with type-1 diabetes.
Materials and methods. FMD of the brachial artery in response to reactive hyperaemia was measured using high-
resolution ultrasonograghy. Young male patients with type-1 diabetes (n ¼ 9) were compared with age matched non-diabetic
controls (n ¼ 8).
Results. The FMD response in the control group was a median increase in diameter of 7.9 (range 3.8–12.6)%. In the
diabetic group the FMD response was impaired when compared with controls with a median increase only of 4.4 (range 3.7–
5.8)% (p , 0.01). Following Pravastatin, 40 mg per day for one month in the diabetic group, there was a significant
diameter change in response to reactive hyperaemia with a median of 8.4 (range 6.9–12.6)% (p , 0.01).
Conclusions. These data confirm the presence of endothelial dysfunction in young patients with type-1 diabetes. We have
shown that 1-month of Pravastatin treatment normalizes FMD. This suggests that HMG CoA reductase inhibitors may
have a role in the management of diabetes mellitus, even in the presence of normal serum cholesterol levels.
Key Words: HMG CoA reductase inhibition; Diabetes mellitus; Endothelial dysfunction; Nitric oxide; Constitutive
endothelial nitric oxide synthase.
Introduction
People with diabetes mellitus suffer accelerated
atherosclerosis and a greater incidence of morbidity
and mortality secondary to premature cardiovascular
disease than in the general population.1,2 Not with-
standing earlier detection of complications and better
glycemic control, additional therapeutic approaches
are clearly required. Endothelial dysfunction, with
diminished nitric oxide production, is an early key
event in the development of atherosclerosis.3,4 The
normal response of a conduit blood vessel to an
increase in blood flow is one of dilation, flow-
mediated dilation (FMD). Patients with type-1 dia-
betes exhibit alterations of FMD, which is a nitric oxide
dependent phenomenon and an easily determined
clinical marker of endothelial function.5,6 The bioavail-
ability of nitric oxide may be related to substrate
availability (i.e. L-arginine), co-factors (i.e. tetrahydro-
biopterin) or the activity of nitric oxide synthase, the
constitutive enzyme required for basal nitric oxide
production.7
The ability of HMG CoA reductase inhibitors to
reduce cardiovascular related morbidity and mortality
has been well established.8 – 10 Patients on statin
therapy have been shown to derive clinical benefits
well before any regression in atherosclerotic plaques
and beneficial effects far exceed changes in plaque
size.11 Matrix metalloproteinase-1 (MMP-1) has been
implicated in plaque rupture by degrading collagens,
fibronectin, elastin, and proteglycans, all important
components of the fibrous cap. Fluvastatin has been
shown to decrease MMP-1 expression in human
vascular endothelial cells providing a potential mech-
anism for stabilization of vulnerable plaques.12 In
addition, work by Essig et al., has shown that statins
can modify the fibrinolytic activity of endothelial cells
by increasing tPA synthesis and release and decreas-
ing PAI-activity, reducing the potential for vascular
thrombosis over the plaque.13
It is now widely accepted that statins have
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beneficial effects beyond cholesterol reduction, with
emerging evidence for direct vascular and cardiopro-
tective effects even in patients with average cholesterol
levels.14 – 16 These observations are supported by
clinical studies showing improved FMD following
their administration to hypercholesterolemic patients
with established abnormalities in endothelial func-
tion.17,18 A potential mechanism of protection with
HMG-CoA reductase inhibitors involves the increased
expression and activity of constitutive endothelial
nitric oxide synthase (ecNOS), predominately by
post-transcriptional stabilization of mRNA.19,20
The aim of this study was to assess if treatment with
pravastatin (40 mg/day) would modulate endothelial
dysfunction, assessed using FMD, in young asympto-
matic patients with type-1 diabetes.
Patients and Methods
Subjects
Subjects were recruited from diabetes outpatient
clinics. They were young males with type-1 diabetes
who had no discernable evidence of macrovascular or
microvascular disease. Impairment of flow-mediated
dilatation, a nitric oxide dependent phenomenon, is
the earliest detectable marker of endothelial dysfunc-
tion, in patients predisposed to atherosclerosis but is
not a technique that is commonly used in assessing
diabetic patients.21 Females were not included in the
study because of the unknown effects of pravastatin on
foetal development and to avoid gender bias due to
the potential difference in reactive hyperaemic
responses previously observed between males and
females.22 These gender differences have been attrib-
uted to the use of oral contraceptive/hormonal
variations but more definitive studies will be required
to confirm these suggested differences.23,24 All patients
underwent fundoscopy to exclude diabetic retinopa-
thy. They also underwent a 24 h collection of urine to
exclude microalbuminuria (i.e. Urinary albumin
excretion rate .20 mg/min), (COBASMIRAS, Roche),
one of the earliest indicators of diabetic renal disease
and a known risk factor for atherosclerosis.25 Other
exclusion criteria included smoking, family history of
premature heart disease, hypertension, hypercholes-
terolemia, and patients on medications other than their
insulin regime. While there is a large pool of patients
with type-1 diabetes attending the clinics only a small
number were suitable for the study due to our strict
inclusion criteria. Similar, non-diabetic aged matched
controls were recruited from hospital staff. The
controls were also subjected to the inclusion criteria.
Prior to commencement of the study all subjects had
baseline liver function and creatinine kinase tests. All
patients had given informed consent to participate in
the study, which was approved by the local ethical
committee.
Vascular reactivity and measure of flow-mediated dilation
The brachial artery was imaged using 13 MHz linear
array transducer ultrasound system (Acuson
128XP/10 system). All scans were performed by the
same operator under standardized conditions (M.J). In
both groups a cannula was inserted into the left
antecubital vein to allow venous blood sampling.
Blood samples were taken to allow measurement of
glycosylated haemoglobin (HA-8140, Menarini),
plasma glucose, total cholesterol, triglycerides, HDL,
LDL (Olympus, AU640), and full blood count (ADVIA
120, Bayer). The diabetic subjects received intravenous
insulin (actrapid), to achieve euglycemia (glucose 3–
6 mmol/l), prior to vascular assessment.
The subjects’ right arm was comfortably immobilized
in the extended position to allow consistent imaging of
the brachial artery. The artery was scanned in longitudi-
nal section with a pulsed Doppler signal at 708 angle to
the vessel, at a location in the ante-cubital fossa where
the clearest anterior posterior M lines (the interface
between the media and the adventicia) were seen. Depth
and gain settings were set to optimise images of the
lumen/arterial wall interface. Images were recorded on
videotape for subsequent off-line analysis using ultra-
sound callipers. The patient rests in a supine position for
ten minutes prior to baseline scanning. The ECG was
monitored continuously throughout the study. Baseline
readings were taken for 2 min. A blood pressure cuff
applied to the distal right forearm was inflated to
240 mmHg for 4.5 min and subsequently deflated. The
cuff is set at wrist level to avoid direct trauma to the
endothelium of the brachial artery, which may lead to
local release of vasoactive substances influencing the
vascular responses. Inflating the cuff distally allows one
to assess the response to changes in blood flow
proximally. The endothelial dependent vasomotor
responses to reactive hyperaemia were then recorded
for subsequent off-line analysis. Diabetic subjects
returned for a second examination after 1-month. The
above technique for assessment of endothelial function
has been extensively described.26–28
Data analysis
Using off-line analysis the baseline brachial artery
diameter and FMD in response to reactive hyperaemia
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were calculated. This was done by two independent
observers blinded to the group from which the scans
were obtained (K.M. and P.F.). This was possible
because all measurements were recorded on video-
tape, stored and analysed at a later stage, offline. The
maximum endothelial response to reactive hyperae-
mia occurs 45–60 s after cuff deflation. Diameter
changes were expressed as the percentage change
relative to the mean baseline scan (100%). Using
ultrasound callipers measurements were taken from
the anterior to the posterior ‘m line’ at the end of
diastole using the ‘m’ mode. The mean diameter was
calculated from four cardiac cycles incident with the
’R’ wave on the ECG.
Statistical methods
Results are presented as median (range). Measurements
of FMD represent the maximum increase in brachial
artery diameter following reactive hyperaemia and are
expressed as a percentage change from baseline
measurements (i.e. resting state). The significance of
differences between the groups for data and clinical
characteristics was tested using nonparametric tests
(Mann–Whitney U test). This was done using the
statistical program SPSS version 10. Statistical signifi-
cance was set at p , 0:05:
Results
Patient characteristics for control and diabetic subjects
are displayed in Table 1. There were no significant
differences between study groups in terms of age,
blood pressure, smoking status, urinary albumin
excretion rate, and baseline levels of total cholesterol,
triglycerides, HDL cholesterol, and LDL cholesterol.
Median duration of diabetes was 12.0 (range 6.0–14.0)
yrs. In this specific diabetic group median glycosy-
lated haemoglobin (HBA1C) was 6.9 (range 4.3–7.4)%
indicating good glycemic control.29 Pravastatin use
was well tolerated and had no adverse effects on
hepatic function.
Euglycaemia was achieved by insulin clamping
with median plasma glucose at time of vascular
reactivity measurements being 5.4 (range 4.7 –
6.2) mmol/l in the control group, 4.9 (range 3.3–
5.6) mmol/l in the diabetic group at baseline and 5.5
(range 4.3–6.0) mmol/l for the diabetic group at 1-
month, with no statistical significant difference
between the groups. FMD in response to reactive
hyperaemia was markedly reduced in the diabetic
group with a median of 4.4% (3.7–5.8)% compared
with the control group which displayed a median of
7.9 (range 3.8–12.6)% ðp , 0:01Þ: However, the diabetic
group showed a statistically significant improvement
in median FMD 8.4 (range 6.9–12.6)% ðp , 0:01Þ;
following 4-weeks of pravastatin treatment (Fig. 1).
These improvements were seen without any statisti-
cally significant change in glycemic control or serum
lipid levels over the treatment period (Fig. 2).
The median resting baseline diameter in the
diabetic group was 4.8 (range 4.5–5.0) mm compared
to 4.0 (range 3.4–4.7) mm in the control group ðp ¼
0:04Þ: This resting vessel diameter in the diabetic
group was restored towards control values following
1-month of treatment with a median of 4.4 (range 3.8–
4.6) mm.
Discussion
Endothelial dysfunction is an early key event in
diabetes mellitus and is believed to be an important
causative factor in the development of atherosclerosis
and associated vascular complications.30,31 Impaired
endothelium dependent relaxation of conduit blood
vessels, an indicator of endothelial dysfunction, has
been extensively confirmed in type-1 diabetes.32,33 The
mechanism by which hyperglycaemia causes endo-
thelial dysfunction has yet to be fully elucidated.
Table 1. Patient characteristics at baseline
Controls ðn ¼ 8Þ Diabetic patients ðn ¼ 9Þ p value
Age (years) 25 (18–30) 23 (19–28) 0.4
Systolic blood pressure (mmHg) 125 (118–140) 130 (122–140) 0.1
Diastolic blood pressure (mmHg) 65 (60–72) 68 (60–90) 0.4
Glycosylated haemoglobin (%) 4.1(3.9–4.6) 6.9 (4.3–7.4) 0.01
Urinary albumin excretion rate (mg/min) 1.8 (1.7–2.0) 2.0(1.7–2.3) 0.1
Total cholesterol (mmol/l) 4.0 (2.4–4.6) 3.9 (3.4–4.8) 0.2
Triglycerides (mmol/l) 1.0 (0.5–1.7) 0.7 (0.6–1.5) 0.7
HDL (mmol/l) 1.4 (1.0–1.6) 1.5 (0.9–1.8) 0.6
LDL (mmol/l) 2.0 (0.7–2.4) 2.3(1.3–2.6) 0.11
Data presented as median (range). Analysis for differences between groups using Mann–Whitney U test. Statistical significance is set at
p , 0:05:
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Potential pathways of mediation involve inactivation
of NO by free radical production or reduced formation
of NO through downregulation of its catalytic enzyme
constitutive endothelial nitric oxide synthase.3,34 The
ability of statin therapy to increase the bioavailability
of NO and restore endothelial function as determined
by measurements of FMD has been demonstrated in a
number of studies in patients with established
atheroma or dyslipidaemia.17,18 In vitro and in vivo
experiments have established that HMG CoA
reductase inhibitors increase the expression and
activity of constitutive endothelial nitric oxide
synthase and do so by stabilization of ecNOS mRNA
rather than induction of ecNOS gene transcription.19,20
This endothelium specific isoenzyme catalyses the
production of nitric oxide from L-arginine, which acts
on underlying smooth muscle to produce vasorelaxa-
tion in response to an increase in shear stress.35 Work
by Feron et al., has also shown that HMG CoA
reductase inhibition with atorvostatin, restores eNOS
activity through downregulation of caveolin-1
expression, suggesting another pathway of action.36
We hypothesized that Pravastatin, a member of the
HMG CoA reductase inhibitor family, would restore
impaired endothelial function in young insulin
dependent diabetics in whom their was no evidence
of dyslipidaemia and who by traditional standards of
assessment had no clinical evidence of macrovascular
or microvascular disease. We tested this hypothesis in
a small group of young healthy males with type-1
diabetes by examining the effect of Pravastatin in a
dose of 40 mg per day on vascular reactivity. Changes
in brachial artery diameter in response to increase flow
(FMD) were determined by ultrasonic insonation
before and after treatment.
In this study, we confirmed that FMD is impaired in
young patients with type-1 diabetes and that this
dysfunction antedates the development of microalbu-
minuria and may be the earliest detectable marker of
risk for atherosclerotoic disease. The administration of
pravastatin to the diabetic subjects was associated
with significant improvements in FMD in response to
reactive hyperaemia (Fig. 1). A significant difference in
baseline diameters between the controls and diabetics
was identified at baseline, with attenuation of this
difference following pravastatin treatment. These
changes are suggestive of interactions between the
micro and macrovasculature. This pathological
peripheral vasodilatation has been previously
documented in the early stages of type-1 diabetes.37
These beneficial effects on the vasculature were
achieved without any significant change in serum
lipid levels or glycemic control, indicating that
pravastatin exerts direct effects on the vascular
endothelium in people with type-1 diabetes.
High-resolution ultrasound imaging to assess arter-
ial diameter responses to an increase in blood flow is
now well established. It is accurate, reproducible and
has been extensively used for the detection of
endothelial dysfunction in diverse groups such as
young active and passive cigarette smokers, patients
with diabetes, in addition to patients with dyslipidae-
mia and atheroma.38 A number of in vivo experiments
have shown that acute hyperglycaemia modulates
endothelium-dependent vasodilation in humans.39 To
circumvent this limitation the diabetic patients were
maintained euglycemic, serum glucose 3–6 mmol/l,
for the assessment period. This was achieved with
insulin clamping and careful titration ensured that no
patient became hypoglycaemic or symptomatic during
the assessment period. Euglycaemia was also achieved
prior to re-assessment of brachial artery reactivity
following the 1-month of pravastatin treatment. This
insulin clamping ensures tight control of confounding
variables, and we believe is necessary when making
serial measurements of endothelial function in
patients with diabetes.40
FMD in diabetic patients has previously been
Fig. 1. Flow-mediated dilation following reactive hyperae-
mia. Scatter plot showing individual values for the 3-groups.
Statistical significance set at p , 0:05: ns, non-significant.
Fig. 2. Median values for total cholesterol, Triglycerides,
HDL and LDL.
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demonstrated to be amenable to therapeutic
manipulation.41,42 This present study reports that the
abnormal FMD in young type-1 diabetics is reversible
by oral administration of the HMG CoA reductase
inhibitor (Pravastatin). A possible explanation for the
baseline diameter differences observed between the
control and diabetics groups may lie in the obser-
vations of Tooke and his colleagues, of the existence of
microvascular dilatation in the early stages of diabetes
mellitus.43 Further studies evaluating the effects of
statin therapy on the microvasculature of this diabetic
group is currently underway.
While pravastatin may not be as potent as other
statins in the immediate reduction of cholesterol
levels, we have identified its potential as an anti-
inflammatory agent and believe that the lipid-low-
ering efficacy of a statin does not necessarily correlate
with its anti-inflammatory properties.44 We appreciate
that in this pilot study the control group were not
re-examined after 1-month and thus we cannot be
certain that observed effects in diabetic patients are not
a time related phenomenon. However, many preced-
ing studies have established the reproducibility of this
technique and accuracy of FMD measurements when
repeated at varying time intervals.38
Abnormal brachial artery reactivity is a reflection of
systemic cardiovascular dysfunction.45 Thus, the
beneficial effects seen at the brachial artery reflect
potential beneficial effects throughout the vascular
endothelium and is consistent with previously
observed effects of statin therapy on coronary and
cerebral circulations but further studies will be
required to determine the extent of this correlation.16,46
The mechanism whereby pravastatin produces its
beneficial effects was not examined. However, exper-
imental evidence suggest that one of the principal
pathways through which statins mediate their effects
involves an increase in the expression and activity of
constitutive endothelial nitric oxide synthase, which
involves stabilization of ecNOS mRNA rather than
induction of ecNOS gene transcription.19,20 We have
confirmed this upregulation in an in vivo experimental
model.44
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